Schremmer Bruno, Manevich Yefim, Feinstein Sheldon I, Fisher Aron B
Institute for Environmental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Subcell Biochem. 2007;44:317-44. doi: 10.1007/978-1-4020-6051-9_15.
All six mammalian peroxiredoxins are expressed in the lung. Peroxiredoxin (Prx) VI is the isoform expressed at the highest level and its lung expression exceeds that for other organs. The predominant location of Prx VI is the cytosol and acidic organelles of Clara cells of the conducting airways and type II epithelial cells and macrophages in the alveoli. Prx I and VI show developmental induction of transcription at birth. PrxVI shares structural homology with other peroxiredoxins exhibiting a thioredoxin fold and a conserved catalytic Cys residue in the N-terminus of the protein. This enzyme is highly inducible by oxidative stress in both the neonatal and adult lung consistent with a role in antioxidant defense. Prx VI has several properties that distinguish its peroxidase activity from other peroxiredoxins: it can reduce phospholipid hydroperoxides in addition to other organic hydroperoxides and H2O2; the electron donor that serves to reduce the oxidized peroxidatic cysteine is not thioredoxin but GSH; instead of homodimerization, heterodimerization with pi-glutathione S-transferase is required for regeneration of the active enzyme. Prx VI also expresses a phospholipase A2 activity that is Ca2+-independent, maximal at acidic pH, and dependent on a serine-based catalytic triad and nucleophilic elbow at the surface of the protein. Models of altered Prx VI expression at the cellular, organ and whole animal levels have demonstrated that Prx VI functions as an important anti-oxidant enzyme with levels of protection that exceed those ascribed to GSH peroxidase (GPx1). The phospholipase A2 activity plays an important role in lung surfactant homeostasis and is responsible for the bulk of the degradation of internalized phosphatidylcholine and its resynthesis by the reacylation pathway. Expression of peroxiredoxins is elevated in several lung diseases including lung cancer, mesothelioma and sarcoidosis, although the mechanism for these alterations is not known. The unique properties of Prx VI enable it to play an important role in lung cell function.
所有六种哺乳动物过氧化物酶体增殖物激活受体在肺中均有表达。过氧化物酶体增殖物激活受体(Prx)VI是表达水平最高的亚型,其在肺中的表达超过其他器官。Prx VI的主要定位是传导气道的克拉拉细胞、II型上皮细胞以及肺泡巨噬细胞的胞质溶胶和酸性细胞器。Prx I和VI在出生时表现出发育性转录诱导。PrxVI与其他过氧化物酶体增殖物激活受体具有结构同源性,呈现硫氧还蛋白折叠结构,且在蛋白质的N端有一个保守的催化半胱氨酸残基。该酶在新生儿和成年肺中均能被氧化应激高度诱导,这与其在抗氧化防御中的作用一致。Prx VI具有多种特性,使其过氧化物酶活性与其他过氧化物酶体增殖物激活受体不同:除了其他有机氢过氧化物和H2O2外它还能还原磷脂氢过氧化物;用于还原氧化的过氧化物半胱氨酸的电子供体不是硫氧还蛋白而是谷胱甘肽(GSH);活性酶的再生需要与π-谷胱甘肽S-转移酶进行异源二聚化而非同源二聚化。Prx VI还表现出一种不依赖Ca2+、在酸性pH下活性最大、依赖于蛋白质表面基于丝氨酸的催化三联体和亲核肘部的磷脂酶A2活性。在细胞、器官和整个动物水平上改变Prx VI表达的模型表明,Prx VI作为一种重要的抗氧化酶发挥作用,其保护水平超过了谷胱甘肽过氧化物酶(GPx1)。磷脂酶A2活性在肺表面活性物质稳态中起重要作用,负责内化磷脂酰胆碱的大部分降解及其通过再酰化途径的重新合成。过氧化物酶体增殖物激活受体的表达在包括肺癌、间皮瘤和结节病在内的几种肺部疾病中升高,尽管这些改变的机制尚不清楚。Prx VI的独特特性使其能够在肺细胞功能中发挥重要作用。